Arbor Pharmaceuticals is led by a team of skilled pharmaceutical veterans, many of whom have experience as healthcare practitioners. Our people fully understand the pharmaceutical development process and value our products can bring to the lives of patients. The Arbor team is now over 300 strong and has full knowledge and capabilities in pharmaceutical research and development, manufacturing, quality control and market commercialization. We work with numerous partners throughout the world for the licensing, manufacturing or development of our marketed and late stage pipeline products.
Arbor Pharmaceuticals has established the goal of becoming the largest privately owned U.S. pharmaceutical company. We are currently working with many of the local universities and discovery centers to identify and keep those innovations in the Atlanta economy through partnerships with Arbor. Our focus is on identifying opportunities that offer improved outcomes for our patients.
For more information, visit arborpharma.com.
At Endo International, our generics and specialty branded products play an important role in helping millions of patients lead healthier lives.
Through our operating companies, we are dedicated to delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization.
For more information about Endo, visit endo.com.
Novo Nordisk is a global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders.
We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 people throughout the country.
For more information, visit novonordisk.us, Facebook, Instagram and Twitter.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.
For more information about Pfizer, please visit: pfizer. com
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
For more information about AbbVie, please visit us at www.abbvie.com.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies. Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.
Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.
For more information, please visit www.ascendispharma.com.
Or, email Ascendis Pharma, Inc. at firstname.lastname@example.org
Intended for US audiences only
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
For more information about Alexion, please visit alexion.com.